Daiichi Sankyo Says Enhertu Approved In EU

What happened

Daiichi Sankyo said Enhertu has been approved in the European Union as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2 positive early breast cancer.

Confirmed

Global impact / market context

An extra approved use lets Daiichi Sankyo sell Enhertu to more patients, supporting revenue, while doctors gain another option after initial treatment for HER2 positive early breast cancer. Adjuvant means treatment given after the main therapy.

Analyst inference

The approval is a product-specific win for Daiichi Sankyo rather than a broad industry event, so it may draw attention from investors weighing the company's drug pipeline against near-term sales expectations.

Analyst inference

What to watch

1. Daiichi Sankyo's statement identifies the EU approval as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2 positive early breast cancer. Confirmed
2. Watch for details on how quickly the company can supply the new use in European markets, since launch timing affects when added revenue can appear. Proposed
3. Track whether doctors adopt the new use widely; slower uptake would limit the sales gain that supports the company's drug revenue outlook. Analyst inference

Evidence

• Original source link unavailable